Neurocrine Biosciences
NASDAQ:NBIXBiotechSan Diego, California, United States · Est. 1992 · 1,100 employees
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine, and psychiatric disorders.
7
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
17
Indications↗
Distinct diseases across all programs
89
Clinical Trials↗
All sponsored trials (all statuses)
27
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
7 drugs in development
Approved1
Phase 34
Phase 25
By Therapeutic Area
top 3
Psychiatry
444%
Neurology
333%
Metabolic & Endocrine
111%
R&D Momentum
56/100
Pipeline Velocity
30/100
Trial Completion Rate
83/100
Pipeline Concentration
33/100
Pipeline Freshness
79/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Key Events
Jun 24, 2026TrialA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
Jun 24, 2026TrialA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Jun 24, 2026TrialA Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Mar 19, 2026TrialPREVAIL: Valbenazine in Chorea of Huntington's
Mar 6, 2026TrialKINESIA-1: Opicapone Adjunct in Parkinson's
Mar 1, 2026TrialEvaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Dec 24, 2025TrialAn Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Dec 1, 2025TrialEfficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
4 more events
Sep 30, 2025TrialPharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Aug 29, 2025TrialA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Aug 18, 2025TrialA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Aug 11, 2025TrialNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$1.2B
Revenue
—
Cash
CEOKevin Gorman
Founded1992
Employees1,100
HQSan Diego, California, United States
ExchangeNASDAQ:NBIX
Websiteneurocrine.com
LinkedInCompany Page
Therapeutic Focus
NeurologyOtherPsychiatryCardiovascularOphthalmologyMetabolic & EndocrineOncology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Neurology
Psychiatry
Metabolic & Endocrine
Neurology
Cerebral Palsy
IngrezzaPhase 3
Huntington Disease
IngrezzaPhase 3
Huntington's Disease
IngrezzaApproved
Parkinson's Disease
IngrezzaApproved
Tardive Dyskinesia
IngrezzaApproved
NBI-1065890Phase 2
Psychiatry
Unknown / Other
Hair-Pulling
IngrezzaApproved
Movement Disorder
IngrezzaApproved
Showing 15 of 20 programs
Regulatory
Regulatory Timeline
19822 events
FDAJan 1
Aldomet — ALDOMET
Application NDA013400 (NDA)
FDAJan 1
Aldomet — ALDOMET
Application NDA018389 (NDA)
19841 event
FDAJun 29
Aldomet — METHYLDOPA
Application NDA018934 (NDA)
20171 event
FDAApr 11
Ingrezza — INGREZZA
Application NDA209241 (NDA)
20243 events
FDADec 13
Crenessity — CRENESSITY
Application NDA218808 (NDA)
FDADec 13
Crenessity — CRENESSITY
Application NDA218820 (NDA)
FDAApr 30
Ingrezza — INGREZZA SPRINKLE
Application NDA218390 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)